R F Frye - JoVE Visualize

Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Policies

Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Policies

Filters

R F Frye

Showing results (41-50 of 46) with videos related to

Pageof 5

Sort By:

You have reached the last page of results.This site can display upto 46 results.

Clinical Pharmacology and Therapeutics|April 29, 1998

Induction of CYP2E1 activity in liver transplant patients as measured by chlorzoxazone 6-hydroxylationG J Burckart, R F Frye, P Kelly, et al.

American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation|March 29, 2001

Cefazolin dialytic clearance by high-efficiency and high-flux hemodialyzersK M Sowinski, B A Mueller, D W Grabe, et al.

Clinical Pharmacology and Therapeutics|May 1, 1996

Pharmacokinetics of abecarnil in patients with renal insufficiencyA H Karara, R F Frye, P E Hayes, et al.

Journal of Clinical Pharmacology|June 27, 2000

Sex differences in the pharmacokinetics of dehydroepiandrosterone (DHEA) after single- and multiple-dose administration in healthy older adultsR F Frye, P D Kroboth, F J Kroboth, et al.

Pharmacotherapy|July 25, 2000

Nalmefene to prevent epidural narcotic side effects in pediatric patients: a pharmacokinetic and safety studyD A Rosen, J L Morris, K R Rosen, et al.

CPT: Pharmacometrics & Systems Pharmacology|January 20, 2016

Pharmacometabolomic Assessments of Atenolol and Hydrochlorothiazide Treatment Reveal Novel Drug Response PhenotypesD M Rotroff, M H Shahin, S B Gurley, et al.

Pageof 5

Search research articles

Showing results (41-50 of 46) with videos related to

Sort By:

Pageof 5

You have reached the last page of results.This site can display upto 46 results.

Clinical Pharmacology and Therapeutics|April 29, 1998

Induction of CYP2E1 activity in liver transplant patients as measured by chlorzoxazone 6-hydroxylationG J Burckart, R F Frye, P Kelly, et al.

American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation|March 29, 2001

Cefazolin dialytic clearance by high-efficiency and high-flux hemodialyzersK M Sowinski, B A Mueller, D W Grabe, et al.

Clinical Pharmacology and Therapeutics|May 1, 1996

Pharmacokinetics of abecarnil in patients with renal insufficiencyA H Karara, R F Frye, P E Hayes, et al.

Journal of Clinical Pharmacology|June 27, 2000

Sex differences in the pharmacokinetics of dehydroepiandrosterone (DHEA) after single- and multiple-dose administration in healthy older adultsR F Frye, P D Kroboth, F J Kroboth, et al.

Pharmacotherapy|July 25, 2000

Nalmefene to prevent epidural narcotic side effects in pediatric patients: a pharmacokinetic and safety studyD A Rosen, J L Morris, K R Rosen, et al.

CPT: Pharmacometrics & Systems Pharmacology|January 20, 2016

Pharmacometabolomic Assessments of Atenolol and Hydrochlorothiazide Treatment Reveal Novel Drug Response PhenotypesD M Rotroff, M H Shahin, S B Gurley, et al.

Pageof 5